<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260698</url>
  </required_header>
  <id_info>
    <org_study_id>GC P#07.01.020</org_study_id>
    <nct_id>NCT04260698</nct_id>
  </id_info>
  <brief_title>Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies</brief_title>
  <official_title>An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamida Cell ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gamida Cell ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omidubicel is an investigational therapy for patients with high-risk hematologic
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient
      number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone
      marrow and regenerating a full array of hematopoietic cell lineages with early and late
      repopulating ability in a timely fashion.

      Omidubicel is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic
      cells from one entire unit of umbilical cord blood. Omidubicel utilizes the small molecule
      nicotinamide (NAM), as an epigenetic approach to inhibit differentiation and to increase the
      migration, bone marrow (BM) homing and engraftment efficiency of hematopoietic progenitor
      cells (HPC) expanded in ex vivo cultures.

      The overall study objectives are to provide access to omidubicel for transplantation in
      patients with hematological malignancies and to collect additional safety and efficacy data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the time from transplant to neutrophil engraftment</measure>
    <time_frame>by day 42 post-transplant inclusive</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>omidubicel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:
Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))
the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>omidubicel</intervention_name>
    <description>hematopoietic stem cell transplant</description>
    <arm_group_label>omidubicel</arm_group_label>
    <other_name>NiCord</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 12 years of age

          -  Applicable disease criteria

          -  Patients must have one or two partially HLA-matched CBUs

          -  Back-up stem cell source

          -  Sufficient physiological reserves

          -  Females of childbearing potential agree to use appropriate method of contraception

          -  Signed written informed consent

        Exclusion Criteria:

          -  Extensive bone marrow fibrosis

          -  Donor specific anti-HLA antibodies

          -  Pregnancy

          -  Medically unsuitable for transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Myers</last_name>
    <phone>+97226595631</phone>
    <email>kelly@gamida-cell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD</last_name>
      <email>GSchiller@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Rezvani,, MD</last_name>
      <phone>650-498-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitchell Horwitz, MD</last_name>
      <phone>919-668-1045</phone>
      <email>mitchell.horwitz@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Maziarz, MD</last_name>
      <phone>503-494-4606</phone>
      <email>maziarzr@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Maziarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

